CN105899485B - 多不饱和羟基脂肪酸的药学上可接受的盐 - Google Patents

多不饱和羟基脂肪酸的药学上可接受的盐 Download PDF

Info

Publication number
CN105899485B
CN105899485B CN201480071412.2A CN201480071412A CN105899485B CN 105899485 B CN105899485 B CN 105899485B CN 201480071412 A CN201480071412 A CN 201480071412A CN 105899485 B CN105899485 B CN 105899485B
Authority
CN
China
Prior art keywords
weight
salt
hetre
pharmaceutical composition
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480071412.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105899485A (zh
Inventor
M·曼库
D·考夫兰
B·唐斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DS Biopharma Ltd
Original Assignee
DS Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DS Biopharma Ltd filed Critical DS Biopharma Ltd
Priority to CN201811061377.2A priority Critical patent/CN109232278A/zh
Publication of CN105899485A publication Critical patent/CN105899485A/zh
Application granted granted Critical
Publication of CN105899485B publication Critical patent/CN105899485B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
CN201480071412.2A 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐 Expired - Fee Related CN105899485B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811061377.2A CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904600P 2013-11-15 2013-11-15
US61/904,600 2013-11-15
PCT/IB2014/003027 WO2015071766A1 (en) 2013-11-15 2014-11-17 Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811061377.2A Division CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Publications (2)

Publication Number Publication Date
CN105899485A CN105899485A (zh) 2016-08-24
CN105899485B true CN105899485B (zh) 2018-10-19

Family

ID=52669635

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480071412.2A Expired - Fee Related CN105899485B (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐
CN201811061377.2A Pending CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811061377.2A Pending CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Country Status (6)

Country Link
US (3) US10017453B2 (enExample)
EP (3) EP3068757B1 (enExample)
JP (3) JP2016538288A (enExample)
CN (2) CN105899485B (enExample)
ES (1) ES2727387T3 (enExample)
WO (1) WO2015071766A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
ES2979124T3 (es) * 2017-03-14 2024-09-24 Ibiden Co Ltd Activador vegetal
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220133669A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387503A (zh) * 1999-11-09 2002-12-25 爱尔康公司 羟基二十碳四烯酸盐,用于治疗干眼病的组合物和方法
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
CN102448453A (zh) * 2009-05-01 2012-05-09 伊奎特德有限公司 多不饱和脂肪酸在治疗神经损伤中的用途
WO2013112876A1 (en) * 2012-01-26 2013-08-01 Dignity Sciences Limited Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055923A (en) * 1960-03-25 1962-09-25 Baxter Laboratories Inc Fatty acid salts
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
DE68924714T2 (de) 1988-01-14 1996-05-02 Anders Frithz Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
AU722625B2 (en) * 1996-09-20 2000-08-10 Atherogenics, Inc. Diagnostics for and mediators of inflammatory disorders
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
DE69927582D1 (de) * 1998-05-15 2006-02-16 Univ Vermont Burlington Neue analoga von 16-hydroxyeicosatetraensäure
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1296923B3 (en) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US9006287B2 (en) 2005-02-14 2015-04-14 Suntory Holdings Limited Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CA2662987A1 (en) 2006-08-08 2008-02-21 Tethys Bioscience, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN104010637A (zh) 2011-10-19 2014-08-27 尊贵科学有限公司 含有双同-γ-次亚麻油酸及/或15-羟基二十碳三烯酸的药物组合物及其使用方法
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
HRP20181418T1 (hr) 2012-01-06 2018-11-30 Omthera Pharmaceuticals Inc. Dpa-obogaćeni pripravci omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
SG10202000496XA (en) 2014-01-10 2020-03-30 Afimmune Ltd Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EP3692986A1 (en) 2014-06-04 2020-08-12 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
EP3399971A1 (en) 2016-01-07 2018-11-14 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387503A (zh) * 1999-11-09 2002-12-25 爱尔康公司 羟基二十碳四烯酸盐,用于治疗干眼病的组合物和方法
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
CN102448453A (zh) * 2009-05-01 2012-05-09 伊奎特德有限公司 多不饱和脂肪酸在治疗神经损伤中的用途
WO2013112876A1 (en) * 2012-01-26 2013-08-01 Dignity Sciences Limited Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Also Published As

Publication number Publication date
EP3068757A1 (en) 2016-09-21
JP6818851B2 (ja) 2021-01-20
JP2016538288A (ja) 2016-12-08
CN105899485A (zh) 2016-08-24
JP2020055825A (ja) 2020-04-09
US10544088B2 (en) 2020-01-28
US10017453B2 (en) 2018-07-10
EP3546446A1 (en) 2019-10-02
EP3878835A1 (en) 2021-09-15
US20150152034A1 (en) 2015-06-04
US20200181064A1 (en) 2020-06-11
US20180118655A1 (en) 2018-05-03
CN109232278A (zh) 2019-01-18
JP2021073194A (ja) 2021-05-13
EP3068757B1 (en) 2019-02-27
WO2015071766A1 (en) 2015-05-21
ES2727387T3 (es) 2019-10-15

Similar Documents

Publication Publication Date Title
JP6818851B2 (ja) 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
RU2556206C2 (ru) Кристаллы
JP2013527246A (ja) リファキシミンの型およびその使用
CN117417263A (zh) Rad1901-2hcl的多晶型形式
ES2729824T3 (es) Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos
WO2024179577A1 (zh) 一种Bcl-2家族蛋白降解剂的药物组合物
US10660963B2 (en) Pharmaceutical composition containing tacrolimus and preparation methods thereof
WO2016078543A1 (zh) 一种盐酸洛氟普啶多晶型物及其制备方法
ES2759874T3 (es) 1,25-Dihidroxivitamina D2 estabilizada y método de preparación de la misma
JP4015954B2 (ja) トシル酸スプラタスト結晶
JP2022526478A (ja) 共結晶形エフィナコナゾール、及びその製造方法
KR20240130669A (ko) 보노프라잔 공형성화물, 및 이의 제조방법
JP2013184902A (ja) リファキシミン含有結晶
HK40016232A (en) Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
HK1229319B (en) Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
HK1229319A1 (en) Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
CN112574330B (zh) 一种舒更葡糖钠晶型
CN105859748B (zh) 多环化合物钠盐及其多晶型、制备方法及应用
CN116199729A (zh) 乙酰氨基阿维菌素晶型b及其制备方法
TW202446392A (zh) 吡啶並吡唑衍生物的藥物組合物及其在醫藥上的應用
WO2017144010A1 (zh) (6-(1H-吲唑-6-基)-N-[4-(4-吗啉基)苯基]咪唑并[1，2-a]吡嗪-8-胺)甲磺酸盐的新晶型
CN118619991A (zh) 一种磷酰胺酯前药及其制备方法和医药用途
CN118512427A (zh) 四氢姜黄素在制备治疗膀胱癌的药物中的用途
CN105237607A (zh) 醋酸乌利司他晶k型物质及制备方法和其组合物与用途
HK40004430B (zh) 9-氨基甲基取代的四环素类化合物的晶型及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Ai Erlandubailin

Patentee after: DS Biopharmaceutical Co.,Ltd.

Address before: Ai Erlandubailin

Patentee before: DS BIOPHARMA Ltd.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20210508

Address after: Ai Erlandubailin

Patentee after: DIGNITY SCIENCES LTD.

Address before: Ai Erlandubailin

Patentee before: DS Biopharmaceutical Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181019

CF01 Termination of patent right due to non-payment of annual fee